Newron Pharmaceuticals SpA

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company that discovers and develops novel therapies for diseases of the central and peripheral nervous system. It offers Xadago (safinamide) for the treatment of Parkinson's disease in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. Its lead compounds include Evenamide, an add-on therapy for schizophrenia and treatment-resistant schizophrenia in Phase III clinical trials, and Ralfinamide for a rare neuropathic pain indication. The company has strategic partnerships with Zambon and Meiji Seika Pharma for the commercialization of safinamide. Founded in 1999, Newron is headquartered in Bresso, Italy.